A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib in Combination with Paclitaxel as First-Line
Study for women with metastatic triple-negative breast cancer using study drug cobimetinib
Sponsor: Hoffmann-La Roche
Enrolling: Male and Female Patients
IRB Number: AAAO6451
U.S. Govt. ID: NCT02322814
Contact: Jessica Segni: 212-305-0170 / js4686@columbia.edu
Additional Study Information: The purpose of this study is to compare the effects, good and/or bad, of study drug cobimetinib and paclitaxel for patients with metastatic truple-negative breast cancer (mTNBC). In this study, you will receive either a combination of cobimetinib and paclitaxel or placebo (no active medication) and paclitaxel. The study will also evaluate what side effects cobimetinib and paclitaxel cause in patients.
This study is closed
Investigator
Kevin Kalinsky, MD, MS
Do You Qualify?
Have you had prior chemotherapy, hormonal, or targeted therapy? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Jessica Segni
js4686@columbia.edu
212-305-0170
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE